vmt diagnostic of parkinson disease
Download
Skip this Video
Download Presentation
VMT Diagnostic of Parkinson Disease

Loading in 2 Seconds...

play fullscreen
1 / 23

VMT Diagnostic of Parkinson Disease - PowerPoint PPT Presentation


  • 75 Views
  • Uploaded on

VMT Diagnostic of Parkinson Disease. You do not have to be a famous boxer or a successful movie star to be concerned about Parkinson. Highlights. Medical device - Diagnostic, simple PC based + internet analysis. Addressing the dire need for effective PD screening test.

loader
I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
capcha
Download Presentation

PowerPoint Slideshow about 'VMT Diagnostic of Parkinson Disease' - dahlia


An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript
highlights
Highlights
  • Medical device - Diagnostic, simple PC based + internet analysis.
  • Addressing the dire need for effective PD screening test.
  • Early diagnosis leads to drug treatment that may delay the deterioration of life quality.
  • Competitive advantage over current manual solutions.
  • Strong value proposition for patients, neurologists and payers (deferring costly care).
  • Large target market- many billions in direct and indirect cost.
  • US Patent 5,772,611, approved in 1998.
  • FDA clearance 510(k) - “evaluation of visuo-motor performance disturbances”.
  • Working Prototype
  • Extensive data base with hundreds of test results
  • Time to Market – Less then a year.

2

background
Background
  • VMT (Visuo-Motor-test) method was developed by Prof. Hocherman, of the faculty of medicine at the Technion.
  • Prof. Hocherman has been involved in basic brain research for over 25 years.
  • VMT was developed within the framework of his research on neurological motor control.
  • The technology and the IP rights are owned by a group of four individuals, Prof. Hocherman included.

3

parkinson disease
Parkinson Disease
  • Parkinson’s disease is the second most common progressive neurodegenerative disorder, after Alzheimer’s disease.
  • ~1.5 million Americans are currently diagnosed with PD and 60,000 new cases are diagnosed each year.
  • More than 2% of the population aged over 65 years are affected.
  • 5%-10% of patients with PD are misdiagnosed (have Parkinson's but are told they have something else),

4

cost of pd direct and indirect
Cost of PD - direct and indirect
  • The financial cost of Parkinson’s Disease to individuals, government and society combined is in the order of $24 billion per year.
  • The study finds that indirect costs - e.g. disability payments by government and insurance plans and lost income due to forced early retirement are $15,000 per patient per year.
  • The direct costs of medicines, surgery, doctor visits, hospitals and nursing homes are $8,800 per patient per year.

5

parkinson neurological degenerative disease
Parkinson Neurological Degenerative Disease
  • The dopaminergic neurons in the Substantia Nigra are gradually depleted and the levels of Dopamine secretion are diminishing.
  • The lack of Dopamine hormones has a devastating effect on motor, cognitive functions & emotional state.

6

vmt product overview
VMTProduct - Overview
  • The enclosure holds the digitizer at elbow’s level and supports the computer monitor, bringing it to eye level.
  • It is designed to allow free hand movement across the digitizer’s plane, while hiding the subject's hand from view.
the product operation
The product - operation
  • TRACING:
    • A path is displayed on screen.
    • The subject moves the cursor along the entire path, as accurately as possible.
  • TRACKING:
    • A target circle moves along the path, at a predeterminedspeed.
    • The subject has to maintain the cursor within the moving target.

8

data analysis complex parameters
Data Analysis - complex parameters
  • The algorithm analyzes and scores the performance in independent tests, comparing Left & Right arms:
    • Test Time.
    • (*)Directional Error (DirEr).
    • (*)Mean percent time of DirEr>50%.
    • Distance from Path.
    • Velocity of hand movement.
    • (*)Number of tracking interruptions.
  • While some of these parameters are standard, the marked (*) measures are unidue to the present system and are protected by patent.

3/08

10

differential diagnosis of pd
Differential diagnosis of PD
  • The VMT was tested on various groups:
    • Early vs. advance PD patients
    • PD Vs. Essential Tremor patients
    • PD Vs. Normal subjects

11

current methods for diagnosis of pd
Current methods for diagnosis of PD

UPDRS is the standard manual scale based on

performance and cognitive tasks. It takes 20-30 min of the neurologist time to complete the test.

SPECT Imaging

Dopamine uptake ligand beta-CIT, a SPECT agent is the most sensitive of biomarkers for the diagnosis of Parkinson's disease.

Beta-CIT targets the dopamine transporter on the dopamine neuronal terminals and quantifies the loss of those terminals.

clinical applications
Clinical Applications
  • Parkinson
    • Screening for early phase PD patients.
    • Differential diagnosis of PD Vs. Essential Tremor and potentially other cognitive & motor dysfunctions.
    • Optimization of drug treatment for PD patients.
  • Non-Parkinson
    • Evaluation of attention disorders (ADD/ADHD).

13

neuroprotection in parkinson s disease
Neuroprotection in Parkinson’s Disease
  • Written by Prof. Shraga Hocherman, :

If a “holy grail” exists in the context of Parkinson’s disease (PD) there is no doubt that it would be a treatment that can slow, stop or even reverse the degeneration of neurons whose death causes the disease

  • Drugs that treat PD symptoms are available, which offer small to modest degree of neuroprotection.
  • New approaches that offer great promise are currently being tested, based on cell biology and genetic engineering.

14

drug treatment disease modification
Drug Treatment - Disease Modification

Care giver or

Nursing home

Early diagnosis of PD

Drug treatment

delays symptoms

Months/years

of active life

15

conclusions from hocherman s publications based on more then 400 patients
Conclusions from Hocherman’s Publicationsbased on more then 400 patients
  • VMT test requires high-level motor planning and cognitive capabilities that are not assessed by the standard diagnostic test - the UPDRS.
  • VisuoMotor coordination of hand movements requires complex cognitive skills, controlling movement direction and velocity. A failure of these high-level motor control systems may occur early in the disease and may even precede the occurrence of motor symptoms.
  • The performance in visuo motor coordination test (VMT) is impaired in early PD patients, either pharmacologically treated or untreated.
  • VMT system maydifferentiate between Essential Tremor patients who may later develop PD and those who wouldn’t.
  • Impaired VMT is a pertinent indication for further SPECT imaging in patients with ET, in order to establish a diagnosis of incipient PD.
  • VMT appears to be a promising, inexpensive and friendly adjunct to the diagnosis of PD.

16

interviews with 3 experts on pd
Interviews with 3 experts on PD
  • Prof. M Youdim - Technion Pharmacology: “Drugs for slowing the deterioration of PD are expected soon (Rasagiline), early detection and treatment are critical”.
  • Prof. H. Bergman - Neurological Physiology, Hadassah: “out of all possible indication, early detection is most important”.
  • Dr. Sharon, Neurologist , Shiba Medical center, Movement Disorders “for PD patients, no single diagnostic modality can replace all other tests, but for monitoring the effects of medicated PD patients, VMT may serve as a objective quantitative tool”.

17

competitive landscape preliminary
Competitive landscape (preliminary)
  • No commercial products for the diagnosis or screening of PD.
  • Existing methods :
    • UPDRS - is the standard manual scale based on performance and cognitive tasks.
    • SPECT & pet CT - both imaging modalities are suggested for evaluating the # of lost neurons.
    • Olfactory - research level claiming that the lost of smelling capability is indicative to PD.

18

advantages
Advantages
  • VMT is a breakthrough computer based diagnostic procedure encompasses a highly desirable diagnostic tool in the movement disorders clinic. There is not a similar system in the market and the comparison is made vs. the traditional diagnostic methods which are time consuming, less accurate and do not provide quantified results:
    • Sensitive and objective system that minimizes false first and second degree errors.
    • Reliable differential diagnosis between PD and its main alternative condition (essential tremor).
    • Provides quantitative estimation of the patient's condition.
    • Cost and time savings - Can be operated by a nurse/technician.
    • Desk top and inexpensive.
    • Easy to install and use.
adhd attention disorder how vmt technology can be used for such an application

ADHD - Attention DisorderHow VMT Technology can be used for such an application

Shraga Hocherman, Emanuel Tirosh, Sharon Dobrovski

Technion, Faculty of Medicine

adhd future development background 1
ADHD Future DevelopmentBackground 1
  • Inattention is one of the basic components of ADHD pathology.
  • ADHD diagnosis relies on daily parents\teachers observations of the child’s behavior, and on a clinical interview, but does not include specific testing of attentional functionality.
  • Behavioral impairments that lead to a diagnosis of ADHD derive in many cases from deficits that are not related to attention.
basic test description
Basic-Test description
  • Basic Test: Move a “mouse” controlled cursor so that it remains within a 1cm target circle that moves along a sinusoidal path from one end of the screen to the other.
  • Loss of the target causes the later to stop in place until re-entered by the cursor.
  • Performance Criteria:Number of target-losing events (Tracking interruptions).Cumulative time of tracking interruptions.Distance from target center.Lateral deviation from the target’s path.Instantaneous directional error.
  • Measurements resolution: 1 millisecond; 0.05 millimeter.
testing with distraction
Testing with distraction
  • Performance under distraction: Target distracters & Cursor distracters.
  • The number and combination of distracters determines the attentional demand of the subject.
  • Assessment of the cost imposed by the attentional load by computing the performance difference between the distracted and the basic task.
  • Low distraction level: 1 target distracter + 1 cursor distracter.
  • High distraction level: 3 target distracters + 3 cursor distracters.
ad